Current Trends in ATRA Delivery for Cancer Therapy.
ATRA
DDSs
cancer
delivery
targeting
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Jul 2020
28 Jul 2020
Historique:
received:
24
06
2020
revised:
23
07
2020
accepted:
25
07
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
All-Trans Retinoic Acid (ATRA) is the most active metabolite of vitamin A. It is critically involved in the regulation of multiple processes, such as cell differentiation and apoptosis, by activating specific genomic pathways or by influencing key signaling proteins. Furthermore, mounting evidence highlights the anti-tumor activity of this compound. Notably, oral administration of ATRA is the first choice treatment in Acute Promyelocytic Leukemia (APL) in adults and NeuroBlastoma (NB) in children. Regrettably, the promising results obtained for these diseases have not been translated yet into the clinics for solid tumors. This is mainly due to ATRA-resistance developed by cancer cells and to ineffective delivery and targeting. This up-to-date review deals with recent studies on different ATRA-loaded Drug Delivery Systems (DDSs) development and application on several tumor models. Moreover, patents, pre-clinical, and clinical studies are also reviewed. To sum up, the main aim of this in-depth review is to provide a detailed overview of the several attempts which have been made in the recent years to ameliorate ATRA delivery and targeting in cancer.
Identifiants
pubmed: 32731612
pii: pharmaceutics12080707
doi: 10.3390/pharmaceutics12080707
pmc: PMC7465813
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
PLoS One. 2015 Jul 17;10(7):e0133414
pubmed: 26186635
Int J Cancer. 2003 Oct 20;107(1):145-8
pubmed: 12925970
Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83
pubmed: 20965219
Eur J Biochem. 2000 Jul;267(14):4315-24
pubmed: 10880953
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9
pubmed: 16849428
World J Clin Oncol. 2015 Dec 10;6(6):212-5
pubmed: 26677433
J Control Release. 2017 Sep 10;261:62-86
pubmed: 28596105
J Cell Physiol. 2011 Feb;226(2):322-30
pubmed: 20836077
J Pharm Pharm Sci. 2003 May-Aug;6(2):292-301
pubmed: 12935441
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1977-81
pubmed: 1848017
Interface Focus. 2015 Oct 6;5(5):20150018
pubmed: 26442142
Stem Cells. 2009 May;27(5):1006-20
pubmed: 19415765
Nat Commun. 2018 Aug 9;9(1):3069
pubmed: 30093655
Genes Dev. 2000 Jan 15;14(2):121-41
pubmed: 10652267
Int J Pharm. 2002 Jul 25;241(2):311-7
pubmed: 12100858
Nat Commun. 2017 Jun 09;8:15772
pubmed: 28598431
Blood. 2016 Jan 7;127(1):29-41
pubmed: 26660431
Theranostics. 2014 Feb 12;4(4):432-44
pubmed: 24578726
Int J Endocrinol. 2018 May 21;2018:2383715
pubmed: 29951093
Cell. 1992 Jan 24;68(2):397-406
pubmed: 1310260
J Control Release. 2003 Jan 9;86(1):33-48
pubmed: 12490371
Chem Biol Interact. 2018 Apr 1;285:69-75
pubmed: 29458017
Cancer Treat Rev. 2014 Jul;40(6):739-49
pubmed: 24480385
Chem Commun (Camb). 2016 Dec 20;53(1):212-215
pubmed: 27918025
Nanotechnology. 2015 Apr 10;26(14):145101
pubmed: 25771790
Haematologica. 2020 Apr 30;:
pubmed: 32354870
Eur J Pharm Biopharm. 2018 Aug;129:184-190
pubmed: 29859281
Colloids Surf B Biointerfaces. 2020 Apr 25;192:110997
pubmed: 32361378
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
Int J Mol Med. 2010 Nov;26(5):723-34
pubmed: 20878095
Asian J Pharm Sci. 2019 Sep;14(5):531-542
pubmed: 32104480
J Clin Med. 2020 Jan 28;9(2):
pubmed: 32012980
Mol Imaging. 2012 Feb;11(1):58-66
pubmed: 22418028
Drug Deliv. 2017 Dec;24(sup1):22-32
pubmed: 29069920
Oncogene. 2003 Oct 20;22(47):7305-15
pubmed: 14576840
J Control Release. 2006 Nov;116(1):58-63
pubmed: 17067713
Mol Pharmacol. 2013 May;83(5):1057-65
pubmed: 23455313
Adv Ther. 2012 Sep;29(9):747-62
pubmed: 22941525
Biomaterials. 2013 May;34(15):3912-23
pubmed: 23453062
Blood. 1999 Oct 1;94(7):2230-5
pubmed: 10498593
Biochem Biophys Res Commun. 2004 Oct 22;323(3):876-83
pubmed: 15381082
Yonsei Med J. 2018 Dec;59(10):1150-1158
pubmed: 30450848
Int J Nanomedicine. 2017 Aug 03;12:5585-5599
pubmed: 28831254
Lancet Haematol. 2015 Sep;2(9):e357-66
pubmed: 26685769
ACS Nano. 2011 Feb 22;5(2):1483-94
pubmed: 21204585
Br J Cancer. 2014 Nov 25;111(11):2039-45
pubmed: 25412233
Nutrients. 2011 Jan;3(1):63-103
pubmed: 21350678
Eur J Pharm Biopharm. 2014 Sep;88(1):226-37
pubmed: 24816129
J Pharm Pharmacol. 2004 Dec;56(12):1527-35
pubmed: 15563759
Biol Pharm Bull. 2013;36(6):892-9
pubmed: 23727912
Biomaterials. 2015 Jan;37:405-14
pubmed: 25453968
Jpn J Cancer Res. 2001 Jan;92(1):42-50
pubmed: 11173543
Int J Nanomedicine. 2018 May 18;13:2921-2942
pubmed: 29849457
ACS Nano. 2017 Sep 26;11(9):8668-8678
pubmed: 28806504
Nutrients. 2019 Apr 13;11(4):
pubmed: 31013870
Therap Adv Gastroenterol. 2019 Jan 22;12:1756284818821560
pubmed: 30719075
Molecules. 2019 Mar 21;24(6):
pubmed: 30901827
J Control Release. 2014 Jan 28;174:177-87
pubmed: 24269968
Biochim Biophys Acta. 2011 Aug;1812(8):1023-31
pubmed: 20970498
Bioconjug Chem. 2014 Dec 17;25(12):2093-100
pubmed: 25385142
Oncotarget. 2017 May 9;8(19):31347-31354
pubmed: 28430626
J Nanobiotechnology. 2018 Dec 1;16(1):99
pubmed: 30501644
Cancer. 2002 Sep 15;95(6):1220-7
pubmed: 12216088
Int J Nanomedicine. 2018 Oct 16;13:6499-6515
pubmed: 30410335
Biotechnol Annu Rev. 2007;13:345-57
pubmed: 17875482
Breast Cancer Res Treat. 2012 May;133(1):75-87
pubmed: 21818590
Biochim Biophys Acta. 2012 Jan;1821(1):213-21
pubmed: 21855651
ACS Appl Mater Interfaces. 2017 Mar 29;9(12):10652-10663
pubmed: 28266839
Drug Deliv. 2017 Nov;24(1):1587-1597
pubmed: 29029595
Nat Rev Cancer. 2005 Nov;5(11):899-904
pubmed: 16327766
Carbohydr Polym. 2015 Aug 1;126:231-9
pubmed: 25933544
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
J Control Release. 2006 Feb 21;110(3):514-21
pubmed: 16360957
Ann Oncol. 2017 Mar 1;28(3):611-621
pubmed: 27993792
Nutr Rev. 1973 Sep;31(9):280-1
pubmed: 4586894
Acta Pharmacol Sin. 2013 Jun;34(6):732-40
pubmed: 23685952
Cell Biosci. 2012 Mar 22;2(1):11
pubmed: 22439772
Anticancer Res. 2015 Dec;35(12):6425-9
pubmed: 26637852
Antimicrob Agents Chemother. 1990 Mar;34(3):381-4
pubmed: 2185689
Nanomedicine (Lond). 2018 May;13(9):981-996
pubmed: 29536804
J Control Release. 2018 Jan 10;269:405-422
pubmed: 29170140
Oncol Lett. 2019 Oct;18(4):3646-3654
pubmed: 31579077
Pharmacol Ther. 2017 May;173:19-33
pubmed: 28132904
Onco Targets Ther. 2018 Sep 25;11:6177-6187
pubmed: 30288053
Adv Pharm Bull. 2020 Jun;10(2):221-232
pubmed: 32373490
Sci Rep. 2017 Mar 06;7:43639
pubmed: 28262728
Front Pharmacol. 2019 May 16;10:447
pubmed: 31156425
Science. 2004 Mar 19;303(5665):1818-22
pubmed: 15031496
Leukemia. 1998 Sep;12 Suppl 1:S37-40
pubmed: 9777894
Sci Rep. 2016 Aug 30;6:32332
pubmed: 27573059
Leuk Res. 2016 Jun;45:68-74
pubmed: 27101150
Blood. 2002 Feb 1;99(3):759-67
pubmed: 11806975
Int J Nanomedicine. 2014 Jul 10;9:3313-24
pubmed: 25045262
J Dtsch Dermatol Ges. 2015 Feb;13(2):118-24
pubmed: 25631128
3 Biotech. 2019 Apr;9(4):159
pubmed: 30944806
J Lipid Res. 2013 Jul;54(7):1761-75
pubmed: 23440512
Macromol Biosci. 2014 Mar;14(3):369-79
pubmed: 24115498
Biomed Pharmacother. 2019 Mar;111:751-764
pubmed: 30612000
Front Pharmacol. 2018 Feb 21;9:125
pubmed: 29527167
Cell Commun Adhes. 2004 Jan-Feb;11(1):13-23
pubmed: 15500294
J Biomed Mater Res B Appl Biomater. 2020 Apr;108(3):619-628
pubmed: 31087625
J Nanosci Nanotechnol. 2016 Feb;16(2):1291-300
pubmed: 27433579
Clin Cancer Res. 2001 Oct;7(10):3034-9
pubmed: 11595692
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7950-5
pubmed: 21498687
Pharm Res. 2011 Apr;28(4):762-75
pubmed: 21116692
Nat Rev Cancer. 2016 Jul;16(7):463-78
pubmed: 27256007
Bioconjug Chem. 2019 Feb 20;30(2):263-272
pubmed: 30452233
Leuk Res. 1994 Aug;18(8):587-96
pubmed: 8065160
Blood. 1994 Jan 1;83(1):10-25
pubmed: 8274729
Pharm Res. 2017 Dec;34(12):2710-2719
pubmed: 29181687
Mol Cell Biochem. 2006 Jul;287(1-2):127-35
pubmed: 16685462
J Neural Eng. 2012 Aug;9(4):046020
pubmed: 22832283
Front Cell Dev Biol. 2019 Dec 06;7:322
pubmed: 31867329
Int J Mol Sci. 2018 Jan 03;19(1):
pubmed: 29301374
Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40
pubmed: 6930676
Drug Des Devel Ther. 2019 Oct 30;13:3753-3772
pubmed: 31802849
J Endocrinol Invest. 2009 Oct;32(9):731-8
pubmed: 19509478
Biomed Pharmacother. 2019 Jul;115:108857
pubmed: 31048191
Mol Aspects Med. 2015 Feb;41:1-115
pubmed: 25543955
Int J Cancer. 2003 Jul 1;105(4):561-7
pubmed: 12712451
Curr Pharm Des. 2017;23(35):5213-5229
pubmed: 28552068
Nat Commun. 2018 Aug 23;9(1):3390
pubmed: 30139933
Oncol Lett. 2015 Jun;9(6):2833-2838
pubmed: 26137156
Adv Drug Deliv Rev. 2015 Aug 30;91:3-6
pubmed: 25579058
Blood. 1992 Jan 15;79(2):299-303
pubmed: 1309668
J Exp Clin Cancer Res. 2019 Jan 8;38(1):10
pubmed: 30621740
Eur J Pharmacol. 2019 Jul 5;854:201-212
pubmed: 30974104
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Leuk Lymphoma. 2006 Jun;47(6):1062-8
pubmed: 16840198
J Control Release. 2017 Jul 28;258:43-55
pubmed: 28501705
Pediatr Int. 2016 Feb;58(2):71-80
pubmed: 26645706
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-65
pubmed: 18558452
Biomed Pharmacother. 2014 Jul;68(6):737-43
pubmed: 25108345
Mol Biosyst. 2011 Feb;7(2):371-8
pubmed: 20877915
Blood. 2001 Jan 1;97(1):73-80
pubmed: 11133744
Oncogene. 2016 Sep 8;35(36):4741-51
pubmed: 26876201
Bioconjug Chem. 2010 May 19;21(5):797-802
pubmed: 20397686
Drug Deliv. 2016 May;23(4):1184-93
pubmed: 26004128
Colloids Surf B Biointerfaces. 2017 Feb 1;150:408-416
pubmed: 27829536
Adv Colloid Interface Sci. 2014 Mar;205:187-206
pubmed: 24369107
World J Stem Cells. 2019 Sep 26;11(9):594-603
pubmed: 31616537
Nanoscale Res Lett. 2018 Dec 4;13(1):391
pubmed: 30515583
Nat Med. 2015 May;21(5):457-66
pubmed: 25849135
Cell. 2011 Aug 19;146(4):633-44
pubmed: 21854987
Cancer. 2008 Feb 1;112(3):596-607
pubmed: 18098270
J Control Release. 2016 Aug 10;235:1-13
pubmed: 27235150
Cancer Chemother Pharmacol. 1997;40(4):335-41
pubmed: 9225952
Nanoscale Res Lett. 2020 May 19;15(1):113
pubmed: 32430641
Leuk Res. 2016 Mar;42:93-104
pubmed: 26818572
Cell. 1991 Aug 23;66(4):663-74
pubmed: 1652368
Front Pharmacol. 2020 Feb 03;10:1676
pubmed: 32116677
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1265-1273
pubmed: 28965424
J Drug Deliv. 2013;2013:898146
pubmed: 23577259
J Neurochem. 1985 Jun;44(6):1771-8
pubmed: 2859355
Mini Rev Med Chem. 2013 Dec;13(14):2026-35
pubmed: 24251805
J Antimicrob Chemother. 2013 Feb;68(2):257-74
pubmed: 23054997
J Immunother. 2007 Sep;30(6):655-62
pubmed: 17667529
J Neurobiol. 2006 Jun;66(7):606-30
pubmed: 16688755
Nat Rev Cancer. 2018 Feb;18(2):117-127
pubmed: 29192213
Clin Cancer Res. 2013 Apr 1;19(7):1651-9
pubmed: 23322901
Cancer Res. 2007 Feb 1;67(3):1019-29
pubmed: 17283134
Theranostics. 2017 Jul 23;7(13):3276-3292
pubmed: 28900509
Blood. 1998 Jul 15;92(2):374-82
pubmed: 9657734
Drug Deliv. 2015 Feb;22(2):145-55
pubmed: 24547737
Curr Opin Pharmacol. 2003 Aug;3(4):338-43
pubmed: 12901941
Nanoscale. 2017 Jan 07;9(1):288-297
pubmed: 27909711
Anticancer Res. 2017 Nov;37(11):5975-5981
pubmed: 29061776
Stem Cells Int. 2016;2016:1740936
pubmed: 27418931
Colloids Surf B Biointerfaces. 2017 Nov 1;159:620-628
pubmed: 28865358
Cancer Res. 2005 Nov 1;65(21):9923-33
pubmed: 16267017
Oncogene. 2003 Apr 3;22(13):2021-33
pubmed: 12673207
Mol Carcinog. 2017 Jul;56(7):1712-1721
pubmed: 28218426
Oncotarget. 2018 Oct 5;9(78):34658-34669
pubmed: 30410666
Blood. 2003 Nov 1;102(9):3371-8
pubmed: 12869515
Arch Biochem Biophys. 1991 Jun;287(2):297-304
pubmed: 1898007
Nat Biotechnol. 2013 Jul;31(7):653-8
pubmed: 23792629
Stem Cell Investig. 2018 Mar 14;5:6
pubmed: 29682513
Int J Nanomedicine. 2018 Jan 25;13:537-553
pubmed: 29416334
Breast Cancer Res Treat. 2003 May;79(1):63-74
pubmed: 12779083
Ann Transl Med. 2015 Aug;3(13):184
pubmed: 26366401
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
pubmed: 19225113
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030